Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloGen Liquid for Knee Osteoarthritis
NCT04835389Phase 1Withdrawn
- Sponsor
- VIVEX Biologics
- Start
- Jun 2021
- Primary completion
- Mar 2022
- Modality
- Biologic
01
Overview
Phase 1, randomised, double-blind trial of AlloGen in osteoarthritis (OA) (2 arms), sponsored by VIVEX Biologics. Primary endpoint: Safety of intra-articular administration at 12 weeks. Planned start Jun 2021; status: withdrawn.
02
Drugs
AlloGen
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04835389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835389.